Thursday, November 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 8, 2026

Coinbase Global Conference: CFO Haas touts “Everything Exchange” push amid volatility, regulation talks

View original at finance.yahoo.com
Coinbase Global Conference: CFO Haas touts “Everything Exchange” push amid volatility, regulation talks Coinbase Global logo Crypto’s Crash May Be Over—These 3 Picks Could Rebound Fast Coinbase Global (NASDAQ:COIN) executives and industry partners discussed crypto market dynamics, U.S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We're going to tokenize everything and over time the technology will become chain native and largely invisible to users

    80% confidence
  • Most Coinbase retail customers hold assets during large declines while active users buy the dip

    80% confidence
  • The market is in a fragmentation era for both protocols and stablecoins, with long-term winners driven by network effects, liquidity, and regulatory compliance

    80% confidence
  • Deribit acquisition is a 1 + 1 equals 3 transaction with post-acquisition volume growth and improved institutional counterparty perception

    80% confidence
  • Coinbase is seeing a shift from speculation to utility, with stablecoins as an example

    80% confidence
  • Coinbase doubled derivatives trading volume year-over-year in both market share and total notional

    80% confidence
  • Coinbase believes there is a win-win solution on stablecoin rewards and yield debate

    80% confidence
  • Coinbase currently custodies over 12% of overall crypto market cap and more than twice the nearest competitor

    80% confidence
  • Coinbase has won 80% of ETF custody so far

    80% confidence
  • OCC charter would provide federal jurisdiction for Coinbase custody business and allow custodying more assets under one license

    80% confidence
  • Coinbase One has grown to nearly 1 million paid subscribers

    80% confidence
  • Coinbase had 30 meetings with SEC in the last year focused on rules around tokenized securities

    80% confidence
  • Some support queues are 80%-90% handled by AI agents in consumer and compliance areas

    80% confidence
  • Coinbase is seeking clear rules on asset classification and which regulator oversees which assets

    80% confidence
  • Coinbase believes the industry can reach crypto market structure legislation this spring

    80% confidence
  • Coinbase works with five G-SIBs and over 250 fintechs and corporates building on its developer toolkits

    80% confidence
  • Coinbase commits to being EBITDA positive in all operating environments

    80% confidence
  • Base platform is experiencing all-time high in transactions driven by agentic commerce and payments use cases

    80% confidence
  • Coinbase bought $1.7 billion of stock through mid-February and board authorized additional $2 billion

    80% confidence
  • Coinbase One credit card offers rewards of up to 4% Bitcoin on spending

    80% confidence
  • Early engagement with equities trading rollout is encouraging, though too early to provide statistics

    80% confidence
  • Current crypto volatility is different from prior downturns such as 2022 because price declines and volatility are really institutionally led

    80% confidence
  • Coinbase closed 10 acquisitions last year with Deribit as the largest and Echo as second-largest

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com